Clene (CLNN)
(Delayed Data from NSDQ)
$3.67 USD
+0.01 (0.27%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $3.68 +0.01 (0.27%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLNN 3.67 +0.01(0.27%)
Will CLNN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CLNN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLNN
Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates
Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates
CLNN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates
Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates
Clene Inc. (CLNN) Reports Q3 Loss, Misses Revenue Estimates
Other News for CLNN
Clene to Present at the Canaccord 45th Annual Growth Conference | CLNN Stock News
Clene (CLNN) Receives Consistent Buy Rating from D. Boral Capital | CLNN Stock News
12 Health Care Stocks Moving In Friday's After-Market Session
Clene (CLNN) Maintains "Buy" Rating with $23 Price Target | CLNN Stock News
Clene provides regulatory update following FDA Type C meeting